Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 8/20 | 0.38 |
| ▸ | PPARA | Q07869 | 8/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987860 | 0.93 | AOC3 (0.40) | AOC3KDM4EALDH1A1TAAR1PPARD | |
| SCHEMBL4987950 | 0.90 | CA12 (0.42) | ALDH1A1PPARGECE1MEN1KMT2A | |
| SCHEMBL4988106 | 0.88 | PPARA (0.42) | AOC3KDM4EALDH1A1TAAR1PPARD | |
| SCHEMBL4990831 | 0.87 | STING1 (0.36) | KDM4EPPARDPPARAPPARGGAA | |
| SCHEMBL4984435 | 0.86 | AOC3 (0.43) | AOC3KDM4EALDH1A1TAAR1ECE1 | |
| SCHEMBL4989725 | 0.83 | TAAR1 (0.46) | ALDH1A1TAAR1PPARDPPARAMEN1 | |
| SCHEMBL4993688 | 0.83 | CA12 (0.40) | ALDH1A1PPARAPPARGMEN1KMT2A | |
| SCHEMBL4986008 | 0.83 | PPARG (0.36) | KDM4EALDH1A1PPARDPPARAPPARG | |
| SCHEMBL4986869 | 0.83 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL4984357 | 0.83 | CYP1A2 (0.51) | KDM4EMEN1KMT2ASTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | AOC3 4541/4885KDM4E 3870/4885ALDH1A1 1484/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | AOC3 4276/4885KDM4E 3684/4885ALDH1A1 1627/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | AOC3 4350/4885KDM4E 3950/4885ALDH1A1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.